Clinical Research and Development of Tuberculosis Diagnostics: Moving From Silos to Synergy

The development, evaluation, and implementation of new and improved diagnostics have been identified as critical needs by human immunodeficiency virus (HIV) and tuberculosis researchers and clinicians alike. These needs exist in international and domestic settings and in adult and pediatric populations. Experts in tuberculosis and HIV care, researchers, healthcare providers, public health experts, and industry representatives, as well as representatives of pertinent US federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, United States Agency for International Development) assembled at a workshop proposed by the Diagnostics Working Group of the Federal Tuberculosis Taskforce to review the state of tuberculosis diagnostics development in adult and pediatric populations

Translational research for tuberculosis elimination: priorities, challenges, and actions

Christian Lienhardt and colleagues describe the research efforts needed to end the global tuberculosis epidemic by 2035

Effects of Metronidazole, Tetracycline, and Bismuth-Metronidazole-Tetracycline Triple Therapy in the Helicobacter pylori SS1 Mouse Model after 1 Day of Dosing: Development of an H. pylori Lead Selection Model

We evaluated the effect of optimized doses and dosing schedules of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline (BMT) triple therapy with only 1 day of dosing on Helicobacter pylori SS1 titers in a mouse model. A reduction of bacterial titers was observable with 22.5 and 112.5 mg of metronidazole per kg of body weight (as well as BMT) given twice daily and four times daily (QID). Two hundred milligrams of tetracycline per kilogram, given QID, resulted in only a slight reduction of H. pylori titers in the stomach. We argue that optimization of doses based on antimicrobial drug levels in the animal and shortened (1 or 2 days) drug administration can be used to facilitate early evaluation of putative anti-H. pylori drug candidates in lieu of using human doses and extended schedules (7 to 14 days), as can be deduced from the results seen with these antimicrobial agents

The development pipeline of new TB drugs.

<p>OBR: optimized background regimen; EBA: Early Bactericidal Activity study; DS-TB: Drug susceptible tuberculosis; MDR-TB: Multi-drug resistant tuberculosis. Sources: the Stop TB Partnership Working Group on New Drugs, 2015—<a href="http://www.newtbdrugs.org/" target="_blank">www.newtbdrugs.org</a>. Details for projects listed can be found at <a href="http://www.newtbdrugs.org/pipeline.php" target="_blank">http://www.newtbdrugs.org/pipeline.php</a> and ongoing projects without a lead compound series identified can be viewed at <a href="http://www.newtbdrugs.org/pipeline-discovery.php" target="_blank">http://www.newtbdrugs.org/pipeline-discovery.php</a>.</p

The development pipeline of new TB diagnostics.

<p>Sources: WHO Global TB Programme, 2015—<a href="http://www.who.int/tb/publications/global_report/en/" target="_blank">http://www.who.int/tb/publications/global_report/en/</a>; Foundation for Innovative New Diagnostics (FIND)— <a href="http://www.finddiagnostics.org/resource-centre/presentations/find_symposium_capetown_2015/index.html" target="_blank">http://www.finddiagnostics.org/resource-centre/presentations/find_symposium_capetown_2015/index.html</a>. Disclaimer: The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization or are preferred over others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.</p